| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
MaxCyte, Inc.$1.14
0 (0%)
F 13Pipeline Score Tools & Services · Commercial
Market Cap
111.41 M
EPS
-0.37
P/E Ratio
-
Value Trade
1.07 M
SEC Financials
Q1 2026Dilution Risk
Revenue
9.65 M
R&D Expenses
3.86 M
Operating CF
-8.17 M
Total Assets
194.47 M
Total Liabilities
26.59 M
Equity
167.89 M
D/E Ratio
12,345
-4.59 %
Week
19.51 %
1 Month
40.37 %
3 Month
-36.2 %
6 Month
-93.88 %
5 Year
-93.88 %
All Time
Cash Data
Cash Position
106.85 M
Monthly Burn
2.72 M
Runway
38.3 mo
Burn Trend
StableSEC Filing
May 13, 2026
Overview
Volume
42.30 K
52 Week Range
0.64 - 2.40
% held by Insiders
7.46 %
% held by Institutions
66.31 %
Enterprise Value
22.04 M
Total Shares
107.12 M
Short %
4.51 %
Float Shares
99.12 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F13
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 10%
Micro Cap (rank 815 of 905)
Percentile RankMaxCyte, Inc. has significant pipeline risk (13/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MXCT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MaxCyte, Inc. (MXCT) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
MXCT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MXCT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MXCT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MXCT Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
MXCT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MXCTMaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
MaxCyte reported a total revenue of $9.7 million for Q1 2026, including $6.2 million in core revenue. The company reiterated its full year revenue guidance of $30-32 million and announced a $10 million share repurchase program. CEO Maher Masoud expressed confidence in their performance and growth strategy, highlighting advancements in their SPL portfolio.
Read more →MXCTMaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026
MaxCyte, Inc. will announce its financial results for Q1 2026 on May 12, 2026, after market close. A conference call will follow at 4:30 p.m. ET to discuss these results. Investors are encouraged to register online for the call, which will also be available via webcast. MaxCyte focuses on cell-engineering technologies to support therapeutic development.
Read more →MXCTMaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 31, 2026
MaxCyte, Inc. has announced the granting of inducement awards to Parmeet Ahuja, its new Chief Financial Officer. The awards include stock options for 375,000 shares and RSUs for 187,500 shares, aimed at incentivizing Ahuja's long-term commitment to the company. These grants comply with Nasdaq Listing Rule 5635(c)(4) and are structured to vest over four years.
Read more →MXCTMaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MaxCyte, Inc. has announced the granting of inducement awards to Parmeet Ahuja, its new Chief Financial Officer. The awards include stock options for 375,000 shares and RSUs for 187,500 shares, aimed at incentivizing his employment. These awards comply with Nasdaq Listing Rule 5635(c)(4) and are structured to vest over four years.
Read more →MXCTMaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance
MaxCyte, Inc. reported its financial results for Q4 and full year 2025, revealing total revenues of $7.3 million for the fourth quarter and $33.0 million for the year. The company anticipates revenue of $30-32 million for 2026, despite facing challenges from a major customer. MaxCyte has made strides in reducing cash burn and expanding its SPL portfolio, positioning itself for potential growth in the cell therapy market.
Read more →MXCTMaxCyte Appoints Parmeet Ahuja as Chief Financial Officer
MaxCyte, Inc. has appointed Parmeet Ahuja as Chief Financial Officer, effective March 30, 2026. Ahuja succeeds Douglas Swirsky and brings over 20 years of finance leadership experience from Agilent Technologies. CEO Maher Masoud expressed confidence in Ahuja's ability to enhance financial operations and support the company's growth strategy.
Read more →MXCTMaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery
MaxCyte has launched ExPERT DTx™, a 96-well electroporation platform designed to improve research and drug discovery. This modular system allows for high throughput transfection with minimal cellular stress, streamlining workflows and enhancing experimental consistency. The platform features advanced software for remote experiment design, maximizing efficiency in laboratory settings.
Read more →MXCTMaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026
MaxCyte, Inc. will announce its fourth quarter and full year 2025 financial results on March 24, 2026. The company will hold a conference call at 4:30 p.m. Eastern Time to discuss these results. Investors are encouraged to register online for the call, which will also be available via a live and archived webcast.
Read more →MXCTMaxCyte Announces Planned CFO Transition in 2026
MaxCyte, Inc. has announced that CFO Douglas Swirsky will transition from his role in the first half of 2026. The company is initiating a search for his successor, and Swirsky will remain in his position until a replacement is appointed. He will continue to support the company in an advisory capacity post-transition. The leadership change is not expected to disrupt operations or strategic priorities.
Read more →MXCTMaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
MaxCyte, Inc. reported its third quarter 2025 financial results, indicating a 16% decrease in total revenue compared to the previous year. The company reiterated its revenue guidance for 2025 and highlighted an operational restructuring aimed at cost reduction and long-term growth. Despite a challenging environment, MaxCyte remains committed to its strategic initiatives and partnerships.
Read more →MXCTMaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025
MaxCyte, Inc. announced it will release its financial results for the third quarter of 2025 on November 5, 2025, after market close. The company will host a conference call at 4:30 p.m. ET to discuss these results. Investors are encouraged to register online in advance to participate in the call.
Read more →MXCTMaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors
MaxCyte has entered a Strategic Platform License agreement with Moonlight Bio to enhance the development of T cell therapies targeting solid tumors. This partnership will leverage MaxCyte's Flow Electroporation technology and ExPERT platform, which are designed for scalable and efficient cell engineering. Moonlight Bio aims to address the challenges faced in treating solid tumors, which represent a significant portion of cancer cases globally.
Read more →MXCTMaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability
MaxCyte, Inc. has announced a significant operational restructuring aimed at reducing costs and aligning resources with its strategic priorities. The plan includes a workforce reduction of about 34%, which is expected to save the company approximately $13.6 million annually. Despite these changes, MaxCyte maintains its focus on advancing cell therapies, although it anticipates a decline in core revenue for 2025.
Read more →MXCTMaxCyte Signs Platform License Agreement with Adicet Bio
MaxCyte has entered a strategic platform license agreement with Adicet Bio, granting the latter rights to use MaxCyte's Flow Electroporation technology and ExPERT platform. This collaboration aims to enhance Adicet's gamma delta T cell therapy programs, which target cancer and autoimmune diseases. MaxCyte will receive licensing fees and potential revenue from related programs.
Read more →MXCTMaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline
MaxCyte has entered into a Strategic Platform License Agreement with Anocca AB to utilize its Flow Electroporation technology and ExPERT platform for developing TCR-T cell therapies. This partnership aims to enhance Anocca's capabilities in scalable manufacturing and clinical development. Anocca has recently achieved GMP compliance for its production facility, further supporting its therapeutic pipeline.
Read more →Competitive Position
How MXCT ranks across every disease it competes inCompetitive Position is a premium feature
See how MXCT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial